University of Santiago de Compostela
Field: Biomedicine
CiMUS, which was set up in the University of Santiago de Compostela in 2011, is a benchmark centre for the connection between basic and applied science in biomedicine. In addition to generating knowledge of disease-related molecular mechanisms addressed on a basic research level, it also contributes to the discovery and application of new therapies and drugs.
The Centre stands out for the translational nature of its work. More than 10 of the drugs developed that have reached the clinical trial stage have become a reference for their various areas (genomics, nanomedicine, theragnostics and drug discovery).
Furthermore, the fact that the centre’s researchers are lead authors for the results published in the most prestigious journals has consistently drawn talent to the centre.
CIMUS aspires to consolidate its position as an international hub for translational biomedicine, channelling the synergic actions of its teams in three major areas: research into the basic mechanisms of disease, precision medicine and drug discovery.
RESEARCH AREAS
Obesity
Genomic medicine
Neurosciences
Drug screening
Cardiovascular
Nanodelivery
Cancer
Theragnostic and proton therapy
funding raised in the period 2020-2023
active spin-offs
publications, 56% with international co-authorship (2020-2023)
active ERCs (2020-2023)
patents granted and 5 licensed (2020-2023)
KEY PROJECTS
The aim of the MyeRIBO project is to use advanced electron microscopy, quantitative proteomics, genome-wide ribosome profiling and murine genetic models to research translation control by specialised ribosomes as a novel mechanism of myelination regulation by glial cells.
Centre PI: Ashwin Woodhoo
Financing institution: ERC Consolidator Grant 2020 – code: 865157
Total funding: 1.860.519,27 €
Centre budget: 1.860.519,27 €
Execution period: Del 01/01/2021 al 30/09/2025
Year granted: 2020
The University of Lille, the University of Lubeck and USC-CIMUS are partners in the WATCH project for the use of cutting-edge technologies in system neuroscience, murine genetics and translational research, identifying the function of ependymal cells and creating new therapies for a range of diseases that impact on healthy ageing.
Centre PI: Rubén Nogueiras
IP Coordinador: Vincent Prevot
Financing institution: ERC Synergy Grant 2018 – code: 810331
Total funding: 9.866.250,26 €
Centre budget: 2.497.500,00 €
Execution period: Del 01/03/201 al 28/02/2026
Year granted: 2019
The aim of the MEFISTO project is to develop a functionalised frame based on nanomaterials capable of interacting with the anterior meniscal tissue, thereby contributing to the regeneration of meniscus damage.
Centre PI: María José Alonso
IP Coordinador: Evelyne Hasler (Geistlich)
Financing institution: European Commission- H2020-NMBP-TR-IND-2018-2020 2019 – code: 810331
Total funding: 5.996.590 €
Centre budget: 482.197,50 €
Execution period: 05/03/2019 – 30/11/2023
Year granted: 2019
The project aims to help EU-OPENSCREEN ERIC offer its added value through the reuse of data and chemical tools by users around the world.
Centre PI: Mabel Loza
IP Coordinador: Wolfgang Fecke
Financing institution: European Commission H2020-EU.1.4.1.1. – Developing new world-class research infrastructures – code: 823893
Total funding: 4.999.563,50 €
Centre budget: 362.062,50 €
Execution period: 01/02/2019 – 31/10/2023
Year granted: 2018
The aim of this project is to create a collaborative structure for implementing genomic medicine as part of Precision Medicine, in coordination with the National Health System. Ángel Carracedo is the programme’s general coordinator.
Centre PI: Ángel Carracedo
IP Coordinador: Ángel Carracedo
Financing institution: ISCIII- IMPaCT – code: IMP/00009
Total funding: 7.249.990 €
Centre budget: 117.562,50 €
Execution period: 01/01/2021 – 31/12/2023
Year granted: 2020
SUSTAINABLE DEVELOPMENT GOALS
Contact
Address. Av. Barcelona. Campus Vida. University of Santiago de Compostela
15782 Santiago de Compostela
Spain
Go up to top